Lixte Biotechnology Holdings (NASDAQ: LIXT) entered into definitive agreements in a registered direct offering with accredited investors for the purchase and sale of approximately $4.3 million of Common Stock and pre-funded and investor warrants at a price of $4.09 per Common Unit, priced at the market under Nasdaq rules. The offering comprised 1,051,342 Common Units or Pre-Funded Units, each consisting of one share of Common Stock or one Pre-Funded Warrant and one Common Warrant exercisable at $3.96 per share, with the Common Warrants exercisable immediately and expiring 60 months from issuance. Gross proceeds totaled approximately $4.3 million, with net proceeds allocated for general corporate purposes and working capital. Spartan Capital Securities LLC served as exclusive placement agent, with Sichenzia Ross Ference Carmel LLP acting as counsel to the company and Kaufman & Canoles PC serving as counsel to the placement agent.
Additional information about LIXTE can be found at https://lixte.com/
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer